G protein-coupled receptors (GPCRs) are not only one of the largest classes of signaling molecules in the human genome, they are also serving as target receptor for about one third of approved drugs. Sensing a great variety of different ligands from protons to proteins they also differ greatly in the likelihood to identify small molecule modulators (‘druggability’).
The panel will discuss past learnings and opportunities of our growing tool box in discovery research to tackle difficult GPCR and other targets.
May 5, 15:30-16:15, room Marriott 1+2
| Name | Position | Institution |
|---|---|---|
| Joerg Hueser | Member, Scientific Advisory Board | Axxam SpA |
| Name | Position | Institution |
|---|---|---|
| Michael Hennig | CEO | leadXproAG |
| Zoë Johnson | CSO/CDO | Molecule to Medicine |
| Frederic Bassilana | Executive Director Discovery Sciences | Novartis Biomedical Research |
Axxam provides integrated early discovery services and solutions across the life sciences industry. We support pharmaceutical and biotech companies, start-ups, patient foundations, and academic groups in their journey from target assessment to lead optimization across all therapeutic areas and target classes. Our services comprise assay development, hit identification (including high-throughput screening), and hit-to-lead activities. For more information, visit www.axxam.com.
